Bio-Path Holdings, Inc. (BPTH) Analysts See $-0.60 EPS

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Logo

Analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to report $-0.60 EPS on August, 21.They anticipate $2.40 EPS change or 80.00 % from last quarter’s $-3 EPS. After having $-0.89 EPS previously, Bio-Path Holdings, Inc.’s analysts see -32.58 % EPS growth. The stock increased 1.84% or $0.22 during the last trading session, reaching $12.18. About 114,134 shares traded. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has declined 50.86% since August 16, 2018 and is downtrending. It has underperformed by 50.86% the S&P500.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States. The company has market cap of $34.49 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction. It currently has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

More notable recent Bio-Path Holdings, Inc. (NASDAQ:BPTH) news were published by: Seekingalpha.com which released: “22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers – Seeking Alpha” on March 06, 2019, also Globenewswire.com with their article: “Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 – GlobeNewswire” published on April 03, 2019, Benzinga.com published: “60 Biggest Movers From Yesterday – Benzinga” on July 18, 2019. More interesting news about Bio-Path Holdings, Inc. (NASDAQ:BPTH) were released by: Benzinga.com and their article: “What A $30,000 Losing Trade Looks Like, And How To Bounce Back – Benzinga” published on March 22, 2019 as well as Seekingalpha.com‘s news article titled: “CLMT, RENN among premarket gainers – Seeking Alpha” with publication date: March 07, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.